Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using the Company's proprietary target discovery technology, and is being developed by us in Phase 3 in rheumatoid arthritis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG.
We have a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.
For all your investor relations questions and to request receipt of press releases, annual reports, and other materials:
VP Corporate Communications & Investor Relations
Mobile: +1 781 460 1784
Tel: +31 6 53 591 999